• CReATe Author Series Ep. 10 - Drs. McHutchison and Benatar on Cognitive and Behavioral Changes in MND

    15 FEB. 2024 · Dr. Caroline McHutchison is a Neuropsychologist and CReATe Clinical Research Scholar at the University of Edinburgh and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Temporal course of cognitive and behavioural changes in motor neuron diseases”.
    29m 50s
  • CReATe Author Series Ep. 9 - Drs. Heatwole and Benatar on Patient Reported Outcome Measures and ALS

    3 ENE. 2024 · Dr. Chad Heatwole is a Professor of Neurology and the Director of the Center for Health and Technology at the University of Rochester Medical Center and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure” and its role as a patient reported outcome measure for ALS.
    36m 1s
  • ALS Untangled Series Ep. 56 - Sodium Chlorite

    15 NOV. 2023 · Sodium chlorite is an experimental drug targeting macrophage activation. It exists in different formulations. An oral formulation has potentially deadly side effects. An IV formulation called NP001 has been in recent trials targeting a subset of people with ALS. Here we review the interesting development of this product and where we expect that to go in the near future.
    22m 14s
  • ALS Untangled Series Ep. 55 - Rituximab

    9 OCT. 2023 · Rituximab is an intravenous product that reduces B lymphocytes. It can help improve strength in patients with myasthenia gravis and multi-focal motor neuropathy, neuromuscular diseases that are caused by circulating antibodies made by B lymphocytes. In this podcast we examine the possible use of rituximab to treat patients with ALS
    12m 37s
  • ALS Untangled Series Ep. 54 - Ozone Therapy

    5 SEP. 2023 · Ozone is an oxidizing agent which has some surprisingly plausible mechanisms by which it could influence ALS progression. It can also be dangerous. The FDA has warned against using it as a treatment for any disease. Further studies are needed to determine whether there is any dose or route of administration that might be safe and effective for use in people with ALS.
    18m 43s
  • ALS Untangled Series Ep. 53 - Astaxanthin

    8 AGO. 2023 · Astaxanthin is a naturally occurring chemical which has plausible mechanisms for treating ALS and appears reasonably safe and well tolerated in non-ALS trials. We look forward to ALS-specific trials planned later this year which should shed important light on whether this is specifically safe for people with ALS, and whether it really can slow ALS progression.
    20m 41s
  • CReATe Author Series Ep. 8 Part I - Drs. Turner and Benatar on Neurofilament Light Chain as Biomarker for ALS

    12 JUN. 2023 · Dr. Martin Turner is a Professor of Clinical Neurology & Neurosciences at the University of Oxford and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal”, and the potential role of NfL as a biomarker for ALS. This is part I of a two part series.
    20m 31s
  • CReATe Author Series Ep. 8 Part II - Drs. Turner and Benatar on Neurofilament Light Chain as Biomarker for ALS

    12 JUN. 2023 · Dr. Martin Turner is a Professor of Clinical Neurology & Neurosciences at the University of Oxford and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal”, and the potential role of NfL as a biomarker for ALS. This is part II of a two part series.
    25m 28s
  • ALS Untangled Series Ep. 52 - Antimycobacterial Antibiotics

    1 MAY. 2023 · There is a theorized association between mycobacteria and ALS, and two published case reports described improvements in ALS-like conditions (both with atypical features) after treatment with antimycobacterial antibiotics. Here we review these in detail and discuss our thoughts on how they might change our approach in certain patients in the future.
    16m 46s
  • ALS Untangled Series Ep. 51 - Corticosteroids

    3 ABR. 2023 · Corticosteroids are a class of medications with well-studied effects on the immune system and some people living with ALS have reported benefits from them online. Here we review the pre-clinical and clinical data. We conclude that there is currently no clear evidence that steroids can slow ALS progression, and they can have many side effects.
    13m 38s
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.
Información
Autor CReATe Consortium
Categorías Salud y forma física
Página web -
Email -

Parece que no tienes ningún episodio activo

Echa un ojo al catálogo de Spreaker para descubrir nuevos contenidos.

Actual

Parece que no tienes ningún episodio en cola

Echa un ojo al catálogo de Spreaker para descubrir nuevos contenidos.

Siguiente

Portada del episodio Portada del episodio

Cuánto silencio hay aquí...

¡Es hora de descubrir nuevos episodios!

Descubre
Tu librería
Busca